Date: 2011-09-30
Type of information: Initiation of preclinical development
phase: 3
Announcement: enrolment of the first patients
Company: PharmaNeuroBoost (Belgium)
Product: PNB01
Action
mechanism: PNB01 is the fixed dose combination of citalopram (Selective Serotonin Reuptake Inhibitors (SSRI) ) and low dose pipamperone (neuroleptic agent).
Disease: major depressive disorder (MDD)
Therapeutic area: CNS diseases - Mental diseases
Country: USA
Trial details:
Latest
news: PharmaNeuroBoost has announced that it enrolled in the USA the first patients in its Phase III study with PNB01 in Major Depressive Disorder. The primary objective of this pivotal study is to show a superior rate of Early and Sustained Responders (ESR) over standard of care citalopram and by this addressing an unmet medical need in the treatment of MDD, a devastating disorder.
